Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport

Future Lipidology

Volumn 2, Issue 3, 2007, Pages 285-301

  Robinson, Jennifer G ^a   Davidson, Michael H ^b  

^a UNIVERSITY OF IOWA   (United States)

^b RADIANT RESEARCH   (United States)

Author keywords

Cardiovascular disease; Emerging therapies; High density lipoprotein cholesterol; Mechanisms; Prevention

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN VACCINE; CLOFIBRATE; ETC 216; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GUGGULSTERONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIPOSOME; NEW DRUG; NICOTINIC ACID; PEPTIDE; PEPTIDE 18A; PEPTIDE D 4F; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHATIDYLINOSITOL; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ALLERGIC RASH; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 34250349572     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.3.285     Document Type: Review

References (125)

1. National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Cirrulation 106, 3143-3421 (2002).
2. Gotto AM Jr. Whitney E, Stein EA et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). Circulation 101. 477-484 (2000).
3. Gordon D, Probstfield J. Garrison R et al.: High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79, 8-15 (1989).
4. Lewis G, Rader D: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96, 1221-1232 (2005).
5. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM: Anti-inflammatory properties of HDL. Circ. Res. 95, 764-772 (2004).
6. Mineo C. Deguchi H, Griffin JH, Shaul PW: Endothelial and antithrombotic actions of HDL. Circ. Res. 98, 1352-1364 (2006).
7. Tall AR, Yvan-Charvet L, Wang N: The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27, 257-260 (2007).
8. Yancey PG, Bortnick AE, Keilner-Weibel G. de la Liera-Moya M, Phillips MC, Rothblat GH: Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 23, 712-719 (2003).
9. O'Brien KD, McDonald TO, Kurjathoor V et al.: Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 785-790 (2005).
10. Massamiri T, Tobias PS, Curtiss LK: Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I. J. Lipid Res. 38, 516-525 (1997).
11. Pownall HCE: The unique role of apolipoprotein A-I in HDL remodeling and metabolism. Curr. Opin. Lipidol. 17, 209-213 (2006).
12. Ory DS: Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ. Res. 95, 660-670 (2004).
13. Zelcer N, Tontonoz P: Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116, 607-614 (2006).
14. Wang N, Lan D, Chen W, Matsuura F, Tall AR: ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl Acad. Sci. USA 101, 9774-9779 (2004).
15. Oram JF, Vaughan AM: ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 99, 1031-1043 (2006).
16. Schmitz G, Langmann T: High-density lipoproteins and ATP-binding cassette transporters as targets for cardiovascular drug therapy. Curr. Opin. Investig. Drugs 6, 907-919 (2005).
17. Joyce CW, Wagner EM, Basso F et al.: ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of p-atherogenic lipoproteins and enhanced atherosclerosis. J. Biol. Chem. 281, 33053-33065 (2006).
18. Out R, Hoekstra M, Meurs I et al.: Total body ABCG1 expression protects against early atherosclerotic lesion development in mice. Arteriosrcler. Thromb. Vasc. Biol. 27, 594-599 (2007).
19. Basso F, Amar MJ, Wagner EM et al.: Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet. Biochem. Biophys. Res. Commun. 351, 398-404 (2006).
20. Wang J, Einarsson C, Murphy C et al.: Studies on LXR- and FXR-mediated effects on cholesterol homeostasts in normal and cholic acid-depleted mice. J. Lipid Res. 47. 421-430 (2006).
21. Claudel T, Staels B, Kuipers F: The farnesold X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25, 2020-2030 (2005).
22. Watanabe M, Houten SM, Wang L et al.: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408-1418 (2004).
23. Jansen H: Hepatic lipase: friend or foe and under what circumstances? Curr. Atheroscler. Rep. 6, 343-347 (2004).
24. Rashid S, Watanabe T, Sakaue T, Lewis G: Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase acivity. Clin. Biochem. 36, 421-429 (2003).
25. Badellino K, Wolfe M, Reilly M, Rader D: Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med. 3, E22 (2005).
26. Duffy D, Rader DJ: Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113, 1140-1150 (2006).
27. Ishida T, Choi SY, Kundu RK et al.: Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J. Biol. Chem. 279, 45085-45092 (2004).
28. Jin W, Marchadler D, Rader DJ: Lipases and HDL metabolism. Trends Endocrinol. Metab. 3, 174-178 (2002).
29. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Welbel G, Williams DL, Phillips MC: Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 40, 781-796 (1999).
30. Zhang S, Picard MH, Vasile E et al.: Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class b type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation 111(2), 3457-3464 (2005).
31. Tall AR, Jiang X-C, Luo Y. Silver D: 1999 George Lyman Duff Memorial Lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20, 1185-1188 (2000).
32. Offermanns S: The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol. Sci. 27, 384-390 (2006).
33. Heeren J, Beisiegel U, Grewal T: Apolipoprotein E recycling: implication for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 442-448 (2006).
34. Barter PJ, Kastelein JJP: Targeting cholesteryl ester transfer protein for the prevention and Management of cardiovascular disease. J. Am. Coll. Cardiol. 47, 492-499 (2006).
35. Boekholdt SM, Sacks FM. Jukema JW et al.: Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels. cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111, 278-287 (2005).
36. Barzillai N, Atzmon G, Schechter C et al.: Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290, 2030-2040 (2003).
37. Hirano K, Yamashita S, Kuga Y et al.: Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15, 1849-1856 (1995).
38. Zhong S, Sharp DS, Grove JS et al.: Increased coronary heart disease in Japanese - American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97, 2917-2923 (1996).
39. Curb JD, Abbott RD, Rodriguez BL et al.: A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. 45, 948-953 (2004).
40. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C: The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 155. 269-281 (2001).
41. Jiang X-C, Bruce C, Mar J et al.: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103, 907-914 (1999).
42. Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC: Macrophage phospholipid transfer protein deficiency and apoE secretion. Impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(1), 190-196 (2007).
43. Tan K, Shiu S, Wong Y, Tam S: Plasma phospholipid transfer protein activity and subclinical inflammation in Type 2 diabetes mellitus. Atherosclerosis 178, 365-370 (2005).
44. Schlitt A, Liu J. Yan D, Mondragon-Escorpizo M, Norin AJ, Jiang X-C: Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim. Biophys. Acta 1733, 187-191 (2005).
45. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 81(4 Suppl. 1), 18B-25B (1998).
46. Horowitz B, Goldberg I. Merab J, Vanni T, Ramakrishnan R, Ginsberg H: Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J. Clin. Invest. 91, 1743-1752 (1993).
47. Hansel B, Giral P, Nobecourt E et al.: Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89, 4963-4971 (2004).
48. Kontush A, Chapman M: Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med. 3, 144-153 (2006).
49. Niu N, Zhu X, Liu Y et al.: Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of Type 2 diabetes in Han Chinese. Diabetes Metab. Res. Rev. 23, 21-25 (2007).
50. Dahlback B, Nielsen L: Apolipoprotein M - a novel player in high-density lipoprotein metabolism and atherosclerosis. Curr. Opin. Lipidol. 17, 291-295 (2006).
51. Sirtori C, Calabresi L, Franceschini G et al.: Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda study. Circulation 103, 1949-1954 (2001).
52. Calabresi L, Sirtori CR, Paoletti R, Franceschini G: Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular events. Curr. Atheroscler. Rep. 8, 163-167 (2006).
53. Bielicki J, Oda M: Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 41, 2089-2096 (2002).
54. Calabresi L, Tedeschi G, Treu C et al.: Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL. J. Lipid Res. 242, 935-942 (2001).
55. Nissen SE, Tsunoda T, Tuzcu EM et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300 (2003).
56. Wang L, Sharifi BG, Pan T, Song L, Yukht A, Shah PK: Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J. Am. Coll. Cardiol. 48, 1459-1468 (2006).
57. Daum U, Langer C, Duverger N et al.: Apolipoprotein A-I (R151C) Paris is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux. J. Mol. Med. 77, 614-622 (1999).
58. Jia Z, Natarajan P, Forte TM, Bielicki JK: Thiol-bearing synthetic pepticles retain the antioxidant activity of apollpoprotein A-IMilano. Biochem. Biophys. Res. Commun. 297, 206-213 (2002).
59. Sacks FM, Brewer HB, Alaupovic P et al.: Selective plasma HDL delipidation and reinfusion: a unique approach for acute HD: therapy in the treatment of cardiovascular disease. Presented at: American Heart Association Scientific Sessions. New Orleans, LA, USA, 7-10 November 2004.
60. Datta G, Chaddha M, Hama S et al.: Effects of increasing hydophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42, 1096-1104 (2001).
61. Navab M, Anantharamaiah GM, Hama S et al.: Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice Independent of plasma cholesterol. Circulation 105, 290-292 (2002).
62. Navab M, Anantharamaiah GM, Reddy ST et al.: Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109(25), 3215-3220 (2004).
63. Van Lenten BJ, Wagner AC, Anantharamaiah GM et al.: Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106, 1127-1132 (2002).
64. Ou J, Ou Z, Jones DW et al.: L-4F, an apolipoprotein A- 1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107, 2337-2341 (2003).
65. Ou Z, Ou J, Ackerman AW, Oldham KT, Pritchard KA Jr: L-4F, an apolipoproteln A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 107, 1520-1524 (2003).
66. Remaley A, Thomas F, Stonik J et al.: Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J. Lipid Res. 44, 828-836 (2003).
67. Gupta H, White CR, Handattu S et al.: Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbits. Circulation 111, 3112-3118 (2005).
68. Davidson MH, McKenney JM, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48, 1774-1781 (2006).
69. McKenney JM, Davidson MH, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48, 1782-1790 (2006).
70. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ: Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47, 537-552 (2006).
71. Brousseau ME, Diffenderfer MR, Millar JS et al.: Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25, 1057-1064 (2005).
72. Lloyd DB. Lira ME, Wood LS et al.: Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. J. Biol. Chem. 280, 14918-14922 (2005).
73. Morehouse L, Sugarman E, Bourassa P. Milici A: The CETP-inhibltor torcetrapib raises HDL and prevents aortic atherosclerosis in rabbits. Presented at: XV International Symposium on Drugs Affecting Lipid Metabolism. Venice, Italy, 24-27 October 2004.
74. Brousseau ME, Schaefer EJ, Wolfe ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505-1515 (2004).
75. Clark RW, Sutfin TA, Ruggeri RB et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490-497 (2004).
76. Matsuura F, Wang N, Chen W, Jiang X-C, Tall AR: HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J. Clin. Invest. 116(5), 1435-1442 (2006).
77. Ishigami M, Yamashita S, Sakai N et al.: Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J. Biochem. 116, 257-262 (1994).
78. Ohta T, Nakamura R, Takata K et al.: Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J. Lipid Res. 36, 696-704 (1995).
79. Millar JS, Brousseau ME, Diffenderfer MR et al.: Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler. Thromb. Vasc. Biol. 26, 1350-1356 (2006).
80. Okamoto H, Yonemori F, Wakitani K et al.: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203-207 (2000).
81. de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose-response study. Circulation 105, 2159-2165 (2002).
82. Kuivenhoven J, de Grooth G, Kawamura H et al.: Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95, 1085-1088 (2005).
83. Ryan US, Rittershaus CW: Vaccines for the prevention of cardiovascular disease. Vasc. Pharmacol. 45, 253-257 (2006).
84. Rittershaus CW, Miller DP, Thomas LJ et al.: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 2106-2112 (2000).
85. Rodrigueza WV, Klimuk SK, Pritchard PH, Hope MJ: Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim. Biophys. Acta 1368, 306-320 (1998).
86. Navab M, Hama S, Hough G, Fogelman AM: Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function. and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation 108, 1735-1739 (2003).
87. Burgess JW, Neville TAM, Rouillard P, Harder Z, Beanlands DS, Sparks DL: Phosphatidylinositol increases HDL-C levels in humans. J. Lipid Res. 46, 350-355 (2005).
88. de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BHR, van Tol A, Dullaart RPF: Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in Type 2 diabetes mellitus. Diabetologia 49, 398-404 (2006).
89. Li AC, Glass CK: PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45, 2161-2173 (2004).
90. Miao B, Zondlo S. Gibbs S et al.: Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 45, 1410-1417 (2004).
91. Naik SU, Wang X, Da Silva JS et al.: Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113(1), 90-97 (2006).
92. Brunham LR, Kruit JK, Pape TD, Parks JS, Kuipers F, Hayden MR: Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ. Res. 99, 672-674 (2006).
93. Ulbricht C, Basch E, Szapary P et al.: Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement. Ther. Med. 13, 279-290 (2005).
94. Szapary PO, Wolfe ML, Bloedon LT et al.: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 290, 765-772 (2003).
95. Evans R, Barish G, Wang Y-X: PPARs and the complex journey to obesity. Nat. Med. 10, 1-7 (2004).
96. Lefebvre P, Chinetti G, Fruchart J-C, Staels B: Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571-580 (2006).
97. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 16, 763-772 (1996).
98. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 45, 185-197 (2005).
99. Committee of Principal Investigators: A co-operative trial in the primary prevention, of ischaemic heart disease using clofibrate. Br. Heart J. 40, 1069-1118 (1978).
100. Coronary Drug Project: Clofibrate and niacin in coronary heart disease. JAMA 231, 360-380 (1975).
101. Tenkanen L, Manttari M, Manninen V: Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: Experience from the Helsinki Heart Study. Circulation 92, 1779-1785 (1995).
102. Rubins HB, Robins SJ, Collins D. et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch. Intern. Med. 162, 2597-2604 (2002).
103. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 165, 1154-1160 (2005).
104. The FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
105. Robins SJ, Collins D, Wittes JT et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285, 1585-1591 (2001).
106. Semple RK, Chatterjee VKK, O'Rahilly S: PPARγ and human metabolic disease. J. Clin. Invest. 116(3), 581-589 (2006).
107. Dormandy J, Charbonnel B, Eckland D. et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
108. Goldberg RB, Kendall DM, Deeg MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 28, 1547-1554 (2005).
109. Mazzone T, Meyer PM, Feinstein SB et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA 296, 2572-2525 (2006).
110. The Dream Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096-1105 (2006).
111. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 294, 2581-2586 (2005).
112. Fagerberg B, Edwards S, Halmos T et al.: Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48, 1716-1725 (2005).
113. Barish GD, Narkar VA, Evans RM: PPARδ: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116, 590-597 (2006).
114. Wang Y-X: Peroxisome-proliferator-activated receptor δ activated fat metabolism to prevent obesity Cell 113, 159-170 (2003).
115. Sprecher DL, Massien C, Pearce G et al.: Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor-δ agonist. Arterioscler. Thromb. Vasc. Biol. 27, 359-365 (2007).
116. McKenney J: New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164, 697-705 (2004).
117. Karpe F, Frayn K: The nicotinic acid receptor - a new mechanism for an old drug. Lancet 363, 1892-1894 (2004).
118. Rubic T, Trottmann M, Lorenz R: Stimulation of CD36 and the key effector of reverse choelsterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol. 67, 411-419 (2004).
119. Cheng K, Wu T-J, Wu KK et al.: Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl Acad. Sci. USA 103, 6682-6687 (2006).
120. McGovern M: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br. J. Diabetes Vasc. Dis. 4, 78-85 (2004).
121. Canner PL, Furberg CD, McGovern ME: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. 97, 477-479 (2006).
122. Pfeffer MA, Sacks FM, Moye LA et al.: Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. J. Am. Coll. Cardiol. 33, 125-130 (1999).
123. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
124. The Long-term Intervention with Pravastatin in Ischemic Disease Study: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
125. Shepherd J, Blauw G, Murphy M et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630 (2002).